User menu

Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study

Bibliographic reference Vigano, M. ; Dengler, T. ; Mattei, M. F. ; Poncelet, Alain ; Vanhaecke, Johan ; et. al. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. In: Transplant Infectious Disease, Vol. 12, no. 1, p. 23-30 (2010)
Permanent URL http://hdl.handle.net/2078.1/34226
  1. 1.  Fishman JA , Emery V , Freeman R , et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007; 21 (2): 149-158.
  2. 2.  Leroy F , Sechet A , Abou Ayache R , et al. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients. Transplant Proc 2006; 38 (7): 2324-2326.
  3. 3.  Pereyra F , Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004; 17 (4): 357-361.
  4. 4.  Fishman JA , Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338 (24): 1741-1751.
  5. 5.  Sia IG , Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000; 13 (1): 83-121.
  6. 6.  Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transpl Infect Dis 2001; 3 (Suppl 2): 44-48.
  7. 7.  Weis M , Kledal TN , Lin KY , et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004; 109 (4): 500-505.
  8. 8.  Muhlestein JB , Horne BD , Carlquist JF , et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000; 102 (16): 1917-1923.
  9. 9.  Hodson EM , Jones CA , Webster AC , et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365 (9477): 2105-2115.
  10. 10.  Koskinen PK , Kallio EA , Tikkanen JM , Sihvola RK , Häyry PJ , Lemström KB. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1999; 1 (2): 115-126.
  11. 11.  Eisen HJ , Tuzcu EM , Dorent R , et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349 (9): 847-858.
  12. 12.  Hill JA , Hummel M , Starling RC , et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007; 84: 1436-1442.
  13. 13.  Zuckermann A , Manito N , Epailly E , et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008; 27 (2): 141-149.
  14. 14.  Lehmkuhl HB , Arizon J , Viganò M , et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009; 88 (1): 115-122.
  15. 15.  Vιtko S , Margreiter R , Weimarc W , et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5 (10): 2521-2530.
  16. 16.  Viganò M , Tuzcu M , Benza R , et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007; 26 (6): 584-592.
  17. 17.  Keogh A , Richardson M , Ruygrok P , et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110 (17): 2694-2700.
  18. 18.  Webster AC , Lee VW , Chapman JR , Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81 (9): 1234-1248.
  19. 19.  Ozaki KS , Câmara NOS , Galante NZ , Camargob LFA , Pacheco-Silva A. Decreased cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients. Int Immunopharmacol 2005; 5 (1): 103-106.
  20. 20.  Marty FM , Bryar J , Browne SK , et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110 (2): 490-500.
  21. 21.  Johnson RA , Wang X , Ma X , Huong S , Huang E. Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-k) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 2001; 75 (13): 6022-6032.
  22. 22.  Ponticelli C. Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl Int 2008; 21 (1): 2-10.
  23. 23.  Valantine H , Zuckermann A. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. J Heart Lung Transplant 2005; 24 (4 Suppl): S185-S190.
  24. 24.  Adam E , Melnick JL , DeBakey ME. Cytomegalovirus infection and atherosclerosis. Cent Eur J Public Health 1997; 5 (3): 99-106.